Asset Details
Do you wish to reserve the book?
Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody
Hey, we have placed the reservation for you!
By the way, why not check out events that you can attend while you pick your title.
Oops! Something went wrong.
Looks like we were not able to place the reservation. Kindly try again later.
Are you sure you want to remove the book from the shelf?
Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody
Do you wish to request the book?
Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody
Please be aware that the book you have requested cannot be checked out. If you would like to checkout this book, you can reserve another copy
We have requested the book for you!
Your request is successful and it will be processed during the Library working hours. Please check the status of your request in My Requests.
Oops! Something went wrong.
Looks like we were not able to place your request. Kindly try again later.
Journal Article
Fluorescent Affibody Peptide Penetration in Glioma Margin Is Superior to Full Antibody
2013
Overview
Fluorescence imaging has the potential to significantly improve neurosurgical resection of oncologic lesions through improved differentiation between normal and cancerous tissue at the tumor margins. In order to successfully mark glioma tissue a fluorescent tracer must have the ability to penetrate through the blood brain barrier (BBB) and provide delineation in the tumor periphery where heterogeneously intact BBB may exist. In this study it was hypothesized that, due to its smaller size, fluorescently labeled anti-EGFR Affibody protein (∼7 kDa) would provide a more clear delineation of the tumor margin than would fluorescently labeled cetuximab, a full antibody (∼150 kDa) to the epidermal growth factor receptor (EGFR).
Cetuximab and anti-EGFR targeted Affibody were conjugated to two different fluorescent dyes (both emitting in the near-infrared) and injected intravenously into 6 athymic mice which were inoculated orthotopically with green fluorescent protein (GFP) expressing human U251 glioma cells. Each mouse was sacrificed at 1-h post injection, at which time brains were removed, snap frozen, sectioned and quantitatively analyzed for fluorescence distribution.
Ex vivo analysis showed on average, nearly equal concentrations of cetuximab and Affibody within the tumor (on average Affibody made up 49±6% of injected protein), however, the cetuximab was more confined to the center of the tumor with Affibody showing significantly higher concentrations at the tumor periphery (on average Affibody made up 72±15% of injected protein in the outer 50 um of the tumor). Further ex vivo analysis of detection studies showed that the Affibody provided superior discrimination for differentiation of tumor from surrounding normal brain.
The present study indicates that fluorescently labeled anti-EGFR Affibody can provide significantly better delineation of tumor margins than a fluorescently labeled anti-EGFR antibody and shows considerable potential for guiding margin detection during neurosurgery.
Publisher
Public Library of Science,Public Library of Science (PLoS)
Subject
/ Antibodies, Monoclonal, Humanized - therapeutic use
/ Biology
/ Brain
/ Cancer
/ Epidermal growth factor receptors
/ Female
/ Glioma
/ Gliomas
/ Green Fluorescent Proteins - metabolism
/ Humans
/ Lesions
/ Ligands
/ Medicine
/ Mice
/ Proteins
/ Receptor, Epidermal Growth Factor - immunology
/ Recombinant Fusion Proteins - blood
/ Recombinant Fusion Proteins - therapeutic use
/ Surgery
/ Tumors
